Company performance
Add to research
Current Price
as of Apr 17, 2025$7.33
P/E Ratio
N/A
Market Cap
$1.01B
Description
Add to research
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
Metrics
Add to research
Overview
- HQSeattle, WA
- SectorHealth Technology
- IndustryBiotechnology
- TickerADPT
- Price$7.33-2.14%
Trading Information
- Market cap$1.01B
- Float95.39%
- Average Daily Volume (1m)2,354,483
- Average Daily Volume (3m)1,948,421
- EPS-$1.08
Company
- Revenue$178.96M
- Rev growth (1yr)5.10%
- Net income-$159.49M
- Gross margin53.95%
- EBITDA margin-74.93%
- EBITDA-$134.08M
- EV$882.02M
- EV/Revenue4.93
- P/EN/A
- P/S5.61
- P/B4.98
- Debt/Equity109.85
Documents
Add to research
SEC Filings
Factset Street Account